

ULLA KIRKEGAARD MADSEN - 9350

Fra: Jens.Agerholm@ucb.com
Sendt: 22. oktober 2012 12:43
Til: ULLA KIRKEGAARD MADSEN - 9350
Emne: Revurdering af tilskud til AED

Sent to GoPro Portal: -1

Til Medicintilskudsnet

I en artikel i Dagens Pharma den 9. oktober 2012¹ kan man læse, at Medicintilskudsnet i forbindelse med revurdering af ATC NO3A har bedt Sundhedsstyrelsen om tal for forbruget af epilepsimedicin. Jeg skal med denne henvendelse opfordre Medicintilskudsnet til at foretage en grundig analyse af disse forbrugstal, herunder også udskrivningsmønstre.

Lyrice (Pregabalin) udgør en meget stor andel af forbruget i denne ATC-gruppe. Lyrice har som bekendt flere indikationer, og baseret på hvad jeg hører i det faglige miljø, er der noget, der tyder på, at Lyrice stort set ikke anvendes til behandling af epilepsi. Hvis det er tilfældet, er de reelle udgifter til epilepsibehandling med tillægsterapier således muligvis væsentligt mindre, end hvad det umiddelbart ser ud til.

Kilde: 1) <http://dagenspharma.dk/2012/10/forbrugerne-er-nu-repraesenteret-i-medicintilskudsnaevnet/>

Med venlig hilsen / Kind regards

Jens Agerholm

Market Access Manager, Denmark

UCB NORDIC A/S
Arne Jacobsens Allé 15
2300 Copenhagen S - Denmark

Tel: + 45 32 46 24 00

Fax: + 45 32 46 24 01

Mobile: + 45 25 60 03 03

jens.agerholm@ucb.com

www.ucb.com

Confidentiality note:

This e-mail is intended for the person (s) to whom it's addressed, and may contain information that's privileged, confidential, or otherwise protected from disclosure. Dissemination, distribution or reproduction of this e-mail by anyone other than it's intended recipients is prohibited. If it's not intended for you, please delete the message from your inbox.

UCB Nordic A/S
Arne Jacobsens Allé 15, 2300 Copenhagen S, Denmark
Tel.: +45 32 46 24 00 - Fax: +45 32 46 24 01 - E-mail: contactucb@ucb.com
CVR-nr.: 26688949 - Managing Director: Flemming Andersen

(Ref: #*UDK0209) [Ref-UDK0209]

Legal Notice: This electronic mail and its attachments are intended solely for the person(s) to whom they are addressed and contain information which is confidential or otherwise protected from disclosure, except for the purpose for which they are intended. Dissemination, distribution, or reproduction by anyone other than the intended recipients is prohibited and may be illegal. If you are not an intended recipient, please immediately inform the sender and return the electronic mail and its attachments and destroy any copies which may be in your possession. UCB screens electronic mails for viruses but does not warrant that this electronic mail is free of any viruses. UCB accepts no liability for any damage caused by any virus transmitted by this electronic mail. (Ref: #*UG1107) [Ref-UG1107]
